Education
About Us
Working with TipRanks
Follow Us
InMed Pharmaceuticals (INM)
NASDAQ:INM
INM Stock Chart & Stats
$1.12
-$0.34(-7.10%)
At close: 4:00 PM EST
$1.12
-$0.34(-7.10%)
Day’s Range― - ―
52-Week Range$0.73 - $7.98
Previous CloseN/A
Volume49.03K
Average Volume (3M)113.41K
Market Cap
$2.22M
Enterprise Value-$7.14M
Total Cash (Recent Filing)$9.60M
Total Debt (Recent Filing)$730.14K
Price to Earnings (P/E)―
Beta3.49
Next Earnings
May 18, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.51
Shares Outstanding2,919,186
10 Day Avg. Volume156,716
30 Day Avg. Volume113,414
Financial Highlights & Ratios
PEG Ratio<0.01
Price to Book (P/B)0.17
Price to Sales (P/S)0.64
P/FCF Ratio-0.41
Enterprise Value/Market Cap-3.22
Enterprise Value/Revenue-1.35
Enterprise Value/Gross Profit-5.10
Enterprise Value/Ebitda0.82
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Low Leverage And Positive EquityLow leverage and consistently positive total equity provide structural financial flexibility, reducing near-term solvency risk and enabling continued R&D spending or strategic options without large debt burdens. This lowers refinancing pressure and supports strategic choices over the next several quarters.
Top-line Momentum And Improving Gross MarginRevenue growth coupled with a materially improved gross margin indicates improving unit economics and some commercial traction. If sustained, this structural trend reduces the required incremental funding per dollar of revenue and improves the long-term path toward operational scalability and profitability.
De-risking Of Lead Programs (INM-901, INM-089)Completion of PK work for INM-901 and advancement of INM-089 toward GLP and pre-IND steps materially de-risks lead assets. Progress on clinical-enabling activities strengthens long-term value drivers, increasing potential for IND filings, partnerships, and non-dilutive milestone revenues over coming quarters.
Bears Say
Persistent Negative Cash Flow And Volatile BurnConsistently negative operating and free cash flow with volatile burn increases structural funding risk. Ongoing cash deficits heighten dependency on dilutive equity financings or asset sales, constraining long-term R&D continuity and strategic flexibility absent sustained cashflow improvement or reliable funding sources.
Operating Losses Far Exceed RevenueOperating and net losses that greatly exceed revenue indicate a structural mismatch between costs and current commercial scale. Without durable revenue scaling or significant cost restructuring, negative margins will continue to erode equity and prolong reliance on external financing over multiple reporting periods.
Regulatory Risk To BayMedica Commercial Business (H.R. 5371)New U.S. legislation targeting certain cannabinoid activities creates structural operational and revenue risk for BayMedica. Potential write-offs, forced divestiture or shutdown would permanently reduce a revenue source, worsen cash generation capacity, and could force accelerated asset impairment or strategic restructuring.
InMed Pharmaceuticals News
INM FAQ
What was InMed Pharmaceuticals’s price range in the past 12 months?
InMed Pharmaceuticals lowest stock price was $0.73 and its highest was $7.98 in the past 12 months.
What is InMed Pharmaceuticals’s market cap?
InMed Pharmaceuticals’s market cap is $2.22M.
When is InMed Pharmaceuticals’s upcoming earnings report date?
InMed Pharmaceuticals’s upcoming earnings report date is May 18, 2026 which is in 74 days.
How were InMed Pharmaceuticals’s earnings last quarter?
InMed Pharmaceuticals released its earnings results on Feb 11, 2026. The company reported -$0.513 earnings per share for the quarter, missing the consensus estimate of N/A by -$0.513.
Is InMed Pharmaceuticals overvalued?
According to Wall Street analysts InMed Pharmaceuticals’s price is currently Overvalued.
Does InMed Pharmaceuticals pay dividends?
InMed Pharmaceuticals does not currently pay dividends.
What is InMed Pharmaceuticals’s EPS estimate?
InMed Pharmaceuticals’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does InMed Pharmaceuticals have?
InMed Pharmaceuticals has 2,919,186 shares outstanding.
What happened to InMed Pharmaceuticals’s price movement after its last earnings report?
InMed Pharmaceuticals reported an EPS of -$0.513 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went down -10.101%.
Which hedge fund is a major shareholder of InMed Pharmaceuticals?
Currently, no hedge funds are holding shares in INM
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
InMed Pharmaceuticals
InMed Pharmaceuticals Inc., a clinical stage pharmaceutical company, researches and develops cannabinoid-based therapies. The company's lead product is INM-755, a cannabinol topical cream, which is in a second Phase I clinical trials for the treatment of epidermolysis bullosa. The company is also involved in developing INM-088, which is in preclinical studies for the treatment of glaucoma; and INM-405 for the treatment of pain. In addition, it engages in the development of cannabinoid-based treatments for various diseases, including dermatology and ocular diseases. Further, the company works on IND-enabling pharmacology and preclinical toxicology studies; and IntegraSyn, an integrated biosynthesis-based manufacturing approach, for synthesizing pharmaceutical-grade cannabinoids. It has a research collaboration agreement with BayMedica Inc. for the manufacturing and testing of novel cannabinoid therapeutics. The company was formerly known as Cannabis Technologies Inc. and changed its name to InMed Pharmaceuticals Inc. in October 2014. InMed Pharmaceuticals Inc. was incorporated in 1981 and is headquartered in Vancouver, Canada.
Technical Analysis
Alaunos Therapeutics
―
―
Xenetic Biosciences
―
Ensysce Biosciences
―
Pasithea Therapeutics Corp
―
Ownership Overview
13.25%
Insiders
6.91% Other Institutional Investors
79.84% Public Companies and
Individual Investors
Options Prices
Currently, No data available
---